← 返回

基于深度学习的 TIL(肿瘤浸润淋巴细胞)评分在原发黑色素瘤中具有预后价值,并可预测黑色素瘤转移中的 PD-1 检查点抑制

英文原题:Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases.

查看英文原题

Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases.

PubMed 2023/06/07(内容时间) EBioMedicine Q1 · IF 11.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

TILs 的评估对原发性黑色素瘤样本具有预后价值,eTILs 可补充分期信息。在未经治疗的转移灶中,eTILs≥12.2% 可预测接受抗 PD-1 为基础治疗的患者生存结局不良。

研究思路结论见上方概要

数字病理学的最新进展使得能够准确且标准化地计数TIL(肿瘤浸润淋巴细胞)(TILs)。在此,我们旨在评估TILs作为百分比电子TIL评分(eTILs),并研究其在皮肤黑色素瘤中的预后和预测相关性。

我们纳入了I至IV期皮肤黑色素瘤患者,并使用苏木精-伊红染色切片进行TIL分析。我们将eTILs作为连续变量和分类变量进行评估,使用已发表的16.6%作为截断值,并应用Cox回归模型评估eTILs与无复发生存、无远处转移生存和总生存期的关联。我们将原发灶的eTILs与配对的转移灶进行了比较。此外,我们根据一线治疗评估了eTILs在未接受治疗的转移灶中的预测相关性。

我们分析了321例原发性皮肤黑色素瘤和191例转移样本。在简单Cox回归中,肿瘤厚度(p < 0.0001)、溃疡存在(p = 0.0001)和eTILs 16.6%(p = 0.0012)被发现是RFS的显著不利预后因素。在多因素Cox回归中,eTILs 16.6%(p = 0.0161)仍显著,并使当前分期降级。原发组织中较低的eTILs与不利的无复发生存(p = 0.0014)和无远处转移生存(p = 0.0056)相关。在针对肿瘤厚度和溃疡调整的多因素Cox回归中,eTILs作为连续变量仍显著(p = 0.019)。当比较同一患者原发组织和相应转移灶中的TILs时,转移灶中的eTILs低于原发性黑色素瘤(p < 0.0001)。在未治疗转移灶中,eTILs >12.2%与接受抗PD-1为基础免疫治疗患者的更长无进展生存期(p = 0.037)和黑色素瘤特异性生存(p = 0.0038)相关。在多因素Cox回归中,乳酸脱氢酶(p < 0.0001)和eTILs 12.2%(p = 0.0130)与不利的黑色素瘤特异性生存显著相关。

展开英文摘要原文

Recent advances in digital pathology have enabled accurate and standardised enumeration of tumour-infiltrating lymphocytes (TILs). Here, we aim to evaluate TILs as a percentage electronic TIL score (eTILs) and investigate its prognostic and predictive relevance in cutaneous melanoma.

We included stage I to IV cutaneous melanoma patients and used hematoxylin-eosin-stained slides for TIL analysis. We assessed eTILs as a continuous and categorical variable using the published cut-off of 16.6% and applied Cox regression models to evaluate associations of eTILs with relapse-free, distant metastasis-free, and overall survival. We compared eTILs of the primaries with matched metastasis. Moreover, we assessed the predictive relevance of eTILs in therapy-na ve metastases according to the first-line therapy.

We analysed 321 primary cutaneous melanomas and 191 metastatic samples. In simple Cox regression, tumour thickness (p < 0.0001), presence of ulceration (p = 0.0001) and eTILs 16.6% (p = 0.0012) were found to be significant unfavourable prognostic factors for RFS. In multiple Cox regression, eTILs 16.6% (p = 0.0161) remained significant and downgraded the current staging. Lower eTILs in the primary tissue was associated with unfavourable relapse-free (p = 0.0014) and distant metastasis-free survival (p = 0.0056). In multiple Cox regression adjusted for tumour thickness and ulceration, eTILs as continuous remained significant (p = 0.019). When comparing TILs in primary tissue and corresponding metastasis of the same patient, eTILs in metastases was lower than in primary melanomas (p < 0.0001). In therapy-na ve metastases, an eTILs >12.2% was associated with longer progression-free survival (p = 0.037) and melanoma-specific survival (p = 0.0038) in patients treated with anti-PD-1-based immunotherapy. In multiple Cox regression, lactate dehydrogenase (p < 0.0001) and eTILs 12.2% (p = 0.0130) were significantly associated with unfavourable melanoma-specific survival. INTERPRETATION: Assessment of TILs is prognostic in primary melanoma samples, and the eTILs complements staging. In therapy-na ve metastases, eTILs 12.2% is predictive of unfavourable survival outcomes in patients receiving anti-PD-1-based therapy. FUNDING: See a detailed list of funding bodies in the Acknowledgements section at the end of the manuscript.

论文信息

作者
Chatziioannou E、Roßner J、Aung TN、Rimm DL、Niessner H、Keim U、Serna-Higuita LM、Bonzheim I
第一作者单位
Department of Dermatology, University of T&#xfc;bingen, Liebermeisterstr. 25, 72076 T&#xfc;bingen, Germany; Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", T&#xfc;bingen, Germany.Germany
通讯作者单位
Department of Dermatology, University of T&#xfc;bingen, Liebermeisterstr. 25, 72076 T&#xfc;bingen, Germany; Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", T&#xfc;bingen, Germany; Department of Dermatology, Venereology and Allergology, Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Charit&#xe9;platz 1, 10117 Berlin, Germany. Electronic address: tobias.sinnberg@med.uni-tuebingen.de.Germany
期刊
EBioMedicine2023 Jul
原文标识
PubMed 37295047 · DOI 10.1016/j.ebiom.2023.104644